Acute coronary syndrome
Conditions
Interventions
case series:no
Sponsors
The Third Xiangya Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female,aged >=18 years; 2. Patients with ACS were clearly diagnosed as ST-segment elevation myocardial infarction, unstable angina pectoris, and non-ST-segment elevation myocardial infarction, met the indications for PCI surgery, and voluntarily accepted PCI treatment; 3. Able to receive dual antiplatelet therapy regimen according to ACCA/AHA guidelines; 4. Subjects agree to the study protocol, follow-up time, and sign the informed consent approved by the ethics committee; 5. Subjects can communicate well with the researcher and complete the study according to the study plan.
Exclusion criteria
Exclusion criteria: 1. Platelet count < 100 x 10^9/L or hemoglobin < 10g/dL; 2. Serious complications occured during perioperative period or before platelet activity detection, or coronary artery bypass grafting (CABG) is planned after PCI; 3. Long-term use of vitamin D supplements, calcium-like agents and other oral anticoagulants: classic warfarin, new direct thrombin inhibitors: cimegatran, dabigatran, new direct Xa inhibitors: apixaban, rivaroxaban, and edoxaban; 4. The patient has serious infection, tumor and hematological diseases; 5. Allergic to aspirin or clopidogrel or ticagrelor; 6. Active bleeding or have bleeding tendency, including the gastrointestinal tract, urinary tract, or vitreous hemorrhage, retinal or recently seen in acute cerebrovascular events mainly include cerebral hemorrhage, cerebral infarction, hypertensive encephalopathy, trauma caused by cerebrovascular disease, cerebrovascular disease of unknown cause or clinical doctors think there is a higher risk of blood of the patients, etc.; 7. CYP3A4 inhibitors such as SSRIs, cimetitidine, diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines, or inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, and omeprazole; 8. Participating in other drug clinical trials; 9. Other clinical reasons considered by clinicians to be unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet reactivity;1,25-dihydroxyvitamin D3; | — |
Countries
China
Contacts
Public ContactYang Guoping
The Third Xiangya Hospital
Outcome results
None listed